Montelukast Unicorn 4 And Montelukast Unicorn 5 4 mg, 5mg Chewable tablets
PDF Leaflet Revision Date: 05 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prophylaxis and chronic treatment of atopic asthma in children.
Dosage (summary)
4 mg daily for ages 2-5; 5 mg daily for ages 6-14, taken in the evening.
Onset of Action / Duration
Onset: 2 hours, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established for use in pregnancy and lactation; contraindicated.
Key Drug Interactions
- Phenobarbital
- Gemfibrozil
- CYP inducers
Contraindications
- Hypersensitivity to montelukast
- Children under 2 years
- Children under 6 years for MONTELUKAST UNICORN 5
Common side effects
- Headache
- Dizziness
- Abdominal pain
- Upper respiratory infection
Counselling Points
- Take daily in the evening
- Do not substitute for corticosteroids abruptly
- Monitor for neuropsychiatric changes
Serious warnings
- Not for acute asthma attacks
- Neuropsychiatric events reported
Important Disclaimer
The Montelukast Unicorn 4 And Montelukast Unicorn 5 4 mg, 5mg Chewable tablets professional information leaflet below is the property of Sandoz Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
